Stability as strategy: The UK’s regulatory position in the wake of the EU Pharmaceutical Package

The EU is overhauling its pharmaceutical legislation. The UK is not. For life sciences companies planning their European launch strategies, that contrast deserves careful analysis.

Introduction

As we discussed in our previous briefing “EU Pharmaceutical Package: The start of the largest reform in over two decades”, the EU is moving from its longstanding foundational structure of regulatory protections—eight years of data protection followed by two years of market protection with potential for a 1 year extension for a new indication (commonly referred to as the “8+2+1” structure) to a modulated 8+1 baseline with conditional extensions (up to a maximum of 11 years). This is coupled with new forced-launch obligations requiring marketing authorisation holders to supply Member States within three years of a request or face the loss of market exclusivity in that state. The EU legislation is expected to be formally adopted in summer 2026 and to become fully applicable some time in 2028.

The UK, by contrast, holds its ground. There is no proposal to reduce or modulate the 8+2 period, no forced-launch mechanism, and no conditionality attaching to the maintenance of exclusivity. The UK’s regulatory framework for medicines remains rooted in the Human Medicines Regulations 2012 (HMR 2012), and the Opinion of the Regulatory Policy Committee published on 23 March 2026 confirms that reform of regulatory protections is not a current UK Government priority. Other changes such as the broadening of the Bolar exemption provisions in the EU will not apply directly in the UK but will likely have practical implications for the UK market. This is due to the fact that since data generated in the EU for marketing authorisation purposes may be relied upon in the UK, earlier EU-based preparatory work could translate into earlier UK filings and launches. Separately, whilst the changes to the orphan drug regime in the EU will not apply in the UK, the UK is pursuing its own reform with the MHRA’s proposed Rare Disease Therapies Regulatory Framework^[1]  and is aiming to finalise a refined and implementable model by the end of 2026.^[2]

That stability is itself significant. Whilst both jurisdictions are pursuing coherent policy objectives, for companies mapping their broader European strategy, the UK’s unique regulatory and commercial position creates a distinct set of options that we explore below. 

The Windsor Framework and the UK-only route

From 1 January 2025, the Windsor Framework introduced a new “Category 1” authorisation route under which medicines authorised by the MHRA can be supplied across the entire United Kingdom—England, Scotland, Wales, and Northern Ireland—without requiring any involvement of the European Medicines Agency (EMA). A single UK-only pack suffices for the whole of the UK market.

The practical significance of this development should not be understated. Prior to the Windsor Framework, the position of Northern Ireland under the Protocol created regulatory complexity that meant, in effect, a UK-wide launch still needed to account for EU regulatory architecture. That constraint has been removed. The UK is now fully decoupled from the EU system for launch planning purposes, and companies can pursue a UK-only regulatory strategy on its own terms and timeline.

MHRA international partnerships and regulatory efficiency

A common concern regarding any single-country regulatory pathway is whether the relevant authority has the capacity and speed to deliver timely approvals. The MHRA has sought to address this through a series of international collaboration mechanisms that draw on the expertise and resources of peer regulators, as well as by improving regulatory efficiency at a national level.

The ACCESS Consortium enables work-sharing arrangements with regulators in Australia, Canada, Singapore, and Switzerland. The EC Decision Reliance Procedure (ECDRP) allows the MHRA to rely upon centralised procedure decisions taken by the EMA, providing an expedited route for products already approved in Europe. Project Orbis facilitates concurrent oncology reviews alongside the FDA, Health Canada, and other participating agencies. 

The trajectory of international cooperation continues to develop. In April 2026, the UK and US announced deepening regulatory cooperation on medical devices through the MHRA-FDA relationship. More significantly for present purposes, a wider US-UK pharmaceutical partnership announced in April 2026 removes tariffs on UK medicines exports and actively encourages companies to launch new treatments in the UK at an earlier stage. 

At national level, the Innovative Licensing and Access Pathway (ILAP) offers an integrated regulatory and health technology assessment pathway designed to accelerate access to innovative medicines.

Taken together, these developments reinforce the direction of travel: the UK is positioning itself as a jurisdiction where efficient, internationally-connected regulatory processes reduce the burden of standalone market entry.

The commercial picture: pricing reform and the VPAG

Of course, to offer a balanced view, we must consider the UK’s commercial environment alongside its regulatory landscape. The well-documented difficulties with UK medicines pricing—in particular, the clawback rates under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG)—have been a source of sustained industry criticism. Major companies have characterised the UK as an unattractive market for investment, and those concerns have been neither unfounded nor trivial.

That said, there are material recent improvements to the commercial proposition. The rebate rate under the VPAG has been reduced from 2026, easing the financial burden on manufacturers. The broader US-UK pharmaceutical partnership announced in April 2026 also supports the commercial case for UK launches by removing export tariffs and signalling governmental commitment to the sector.

The longer-term trajectory of UK pricing and reimbursement remains to be seen, and we would counsel against treating recent reforms as a settled resolution. However, the direction of travel is positive, and the gap between the UK’s regulatory attractiveness and its commercial attractiveness is narrowing.

Practical implications: the UK as a piece on the chessboard

The threads above come together to form a coherent picture. The combination of stable intellectual property protections (free from the EU’s new forced-launch-or-lose-exclusivity mechanism), a streamlined UK-only authorisation route via the Windsor Framework, efficient MHRA processes bolstered by international partnerships, and improved commercial terms means that the UK merits serious consideration as a strategic launch destination.

We frame this in measured terms. The UK’s approach may prove to be a useful piece on the chessboard for companies looking at their broader European strategy. A launch in the UK does not trigger the EU’s multi-state supply obligations and sits outside potential most-favoured-nation pricing cascades of the kind discussed in our companion EU briefing. For companies navigating the interaction between US pricing policy developments and EU market entry decisions, the UK offers an established market that operates independently of both frameworks – a new optionality that merits consideration.

Looking ahead

Several developments warrant monitoring in the coming months and years: whether the UK Government revisits regulatory protections in a future review cycle; how alignment between the MHRA approval pathway and NICE health technology assessment continues to evolve; the deepening of US-UK regulatory cooperation and its practical effects on launch timelines; and the broader trajectory of US most-favoured-nation pricing policy and its implications for global launch strategy. We will continue to advise on these matters as they develop.
 

^[1] Policy paper “Rare therapies and UK regulatory considerations”: https://www.gov.uk/government/publications/rare-therapies-and-uk-regulatory-considerations/rare-therapies-and-uk-regulatory-considerations

^[2] Open consultation “Draft rare disease therapies regulatory framework”: https://www.gov.uk/government/consultations/draft-rare-disease-therapies-regulatory-framework/draft-rare-disease-therapies-regulatory-framework